Novel Schizophrenia Therapeutics By Virtual High-Throughput Screening
Novel Schizophrenia Therapeutics By Virtual High-Throughput Screening
批准号:
7361172
负责人:
Jens Meiler
金额:
$19.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-12-19 至 2009-11-30
关键词:
AdoptedAlgorithmsBinding SitesBiologicalBiological Neural NetworksBlood - brain barrier anatomyChemical StructureChemicalsCognitiveCollaborationsComplexComputer softwareDatabasesDevelopmentDiseaseEducationFundingGenerationsGeneticGenetic ProgrammingHalf-LifeHandInternetInvestmentsLeadLibrariesMachine LearningMapsMembraneMembrane ProteinsMetabotropic Glutamate ReceptorsMethodsMiningModelingMolecular BankPharmaceutical PreparationsPrincipal InvestigatorPropertyProteinsPurposeResearchResearch PersonnelSchemeSchizophreniaScreening ResultScreening procedureStructureSystemTechniquesTherapeuticUnited States National Institutes of HealthWorkbasechemical synthesischeminformaticscognitive functioncomputerized toolsdesigndrug developmentexperiencehigh throughput screeninginnovationmathematical modelnovelpharmacophoreprogramsprotein structureresearch studysmall moleculetherapeutic targettoolvirtual
中文摘要
描述(申请人提供):代谢型谷氨酸受体亚型mGluR5的选择性增强剂具有开发精神分裂症和其他扰乱认知功能的障碍的新治疗策略的令人兴奋的潜力。最新一代的选择性mGluR5增强剂是以先导化合物CDPPB为基础的,具有系统活性的化合物具有较长的半衰期,可以穿越血脑屏障。
范德比尔特NIH资助的分子库筛选中心网络设施对mGluR5增强剂的高通量筛选(HTS)揭示了大约1400种物质的大量和多样化的集合,这些物质的活性在独立实验中得到了验证。目前的化学信息学提案旨在利用人工神经网络(ANN)和支持向量机(SVMs)等最新机器学习技术的能力,对HTS结果中反映的mGluR5增强剂的化学结构和生物活性之间的复杂关系进行建模。开发了一种创新的编码方案,允许将不同的化学空间映射到单个数学模型中。由此产生的定量结构活性关系(QSAR)模型将达到三重目的:(A)将获得全面的结合位点药效团,以便于了解SAR并使进一步的实验合理化;(B)这些模型将用于虚拟筛选Vanderbilt高温超导已知但实际无法获得的数百万化合物的文库,以获得获取或合成的优先列表;以及(C)与现有的遗传算法(GA)结构生成器相结合,将优化现有的先导化合物,并设计新的结构以确定潜在的新合成目标。
总体而言,我们不仅希望鉴定mGluR5的新型变构增强剂,并了解它们作为精神分裂症和其他认知功能障碍潜在治疗药物的活性,还希望建立一个创新的化学信息学软件和数据库工具,可以用于其他NIH分子文库筛选中心的研究。开发的应用程序将通过深度集成在药物开发流水线中的WWW接口,为学术研究提供免费和方便的访问。所采用的QSAR模型不需要目标蛋白质的晶体结构。因此,该方法可以很容易地应用于膜蛋白--如GPCRs--现代药物中40%-50%的靶标。
该提案的PI在使用神经网络和支持向量机预测有机分子和蛋白质的性质(1-9)、求解蛋白质结构(10-15)和预测治疗药物的活性(16)方面拥有丰富的经验。他实现了用于化学结构设计和优化的遗传算法(17,18)。对于手头的任务,他与杰夫·康恩合作,杰夫·康恩是研究mGluRs(19)和针对这些系统的潜在疗法(20-22)的著名专家。
英文摘要
DESCRIPTION (provided by applicant): Selective potentiators of the metabotropic glutamate receptor subtype mGluR5 have exciting potential for development of novel treatment strategies for schizophrenia and other disorders that disrupt cognitive function. The latest generation of selective mGluR5 potentiators is based on the lead compound CDPPB and features systemically active compounds with long half-lives that cross the blood-brain barrier.
A high-throughput screen (HTS) for mGluR5 potentiators at Vanderbilts NIH-funded molecular libraries screening center network facility revealed a large and diverse set of about 1400 substances whose activity was validated in independent experiments. The present ChemInformatics proposal targets utilizing the power of recent machine learning techniques such as Artificial Neural Networks (ANNs) and Support Vector Machines (SVMs) to model the complex relationship between chemical structure and biological activity of mGluR5 potentiators reflected in the HTS results. An innovative encoding scheme is developed that allows mapping of the diverse chemical space into a single mathematical model. The resulting Quantitative Structure Activity Relation (QSAR) models will serve a three-fold purpose: (a) a comprehensive binding site pharmacophore will be obtained to facilitate understanding of the SAR and rationalize further experiments; (b) the models will be used to virtually screen libraries of millions of compounds which are known but not physically available for HTS at Vanderbilt to gain a priority list for acquisition or synthesis; and (c) in combination with an existing Genetic Algorithm (GA) structure generator existing lead compounds will be optimized and new structures will be designed to identify potential new targets for synthesis.
Overall we hope to not only identify novel allosteric potentiators of mGluR5 and understand their activity as potential treatment of schizophrenia and other disorders that disrupt cognitive function, but also to build an innovative ChemInformatics software and database tool which can be adopted for research in other NIH molecular libraries screening centers. The developed applications will be made freely and readily accessible for academic research using a WWW interface deeply integrated in the drug development pipeline. The employed QSAR models require no crystal structure of the target protein. Hence the method can be readily applied to membrane proteins-such as GPCRs-which are target of 40-50% of modern medicinal drugs.
The PI of the proposal has extensive experience in the usage of ANNs and SVMs to predict properties of organic molecules and proteins (1-9), solve protein structures (10-15), and predict activity of therapeutics (16). He implemented GAs for the design and optimization of chemical structures (17,18). For the tasks at hand he teams up with Jeff Conn, a renowned expert for researching mGluRs (19) and potential therapeutics targeting these systems (20-22).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural Determinants of Allosteric Modulation of Brain GPCRs
-
批准号:10207579
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2019
-
负责人:Jens Meiler
-
依托单位:
Structural Determinants of Allosteric Modulation of Brain GPCRs
-
批准号:9979812
-
项目类别:
-
资助金额:$39.48万
-
财政年份:2019
-
负责人:Jens Meiler
-
依托单位:
Structural Determinants of Allosteric Modulation of Brain GPCRs
-
批准号:10450746
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2019
-
负责人:Jens Meiler
-
依托单位:
Structural Determinants of Allosteric Modulation of Brain GPCRs
-
批准号:10650803
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2019
-
负责人:Jens Meiler
-
依托单位:
Structural Determinants of Human Antibodies neutralizing the Ebola Virus
-
批准号:9304960
-
项目类别:
-
资助金额:$23.54万
-
财政年份:2016
-
负责人:Jens Meiler
-
依托单位:
Small Molecule Probes to Investigate Structure and Function of Y Receptors
-
批准号:8578312
-
项目类别:
-
资助金额:$35.2万
-
财政年份:2013
-
负责人:Jens Meiler
-
依托单位:
Small Molecule Probes to Investigate Structure and Function of Y Receptors
-
批准号:8890156
-
项目类别:
-
资助金额:$33.95万
-
财政年份:2013
-
负责人:Jens Meiler
-
依托单位:
Computational Design of Protein-Ligand Interfaces - a Therapeutic Strategy
-
批准号:8372321
-
项目类别:
-
资助金额:$29.63万
-
财政年份:2012
-
负责人:Jens Meiler
-
依托单位:
Computational Design of Protein-Ligand Interfaces - a Therapeutic Strategy
-
批准号:8854103
-
项目类别:
-
资助金额:$29.63万
-
财政年份:2012
-
负责人:Jens Meiler
-
依托单位:
Computational Design of Protein-Ligand Interaces - a Therapeutic Strategy
-
批准号:8551916
-
项目类别:
-
资助金额:$2.51万
-
财政年份:2012
-
负责人:Jens Meiler
-
依托单位:
Computational Design of Protein-Ligand Interfaces - a Therapeutic Strategy
-
批准号:8664893
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2012
-
负责人:Jens Meiler
-
依托单位:
Computational Design of Protein-Ligand Interfaces - a Therapeutic Strategy
-
批准号:8519134
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2012
-
负责人:Jens Meiler
-
依托单位:
Cheminformatics of Allosteric mGluR Modulation promotes Therapeutic Development
-
批准号:8416380
-
项目类别:
-
资助金额:$37.05万
-
财政年份:2010
-
负责人:Jens Meiler
-
依托单位:
Cheminformatics of Allosteric mGluR Modulation promotes Therapeutic Development
-
批准号:7863437
-
项目类别:
-
资助金额:$38.74万
-
财政年份:2010
-
负责人:Jens Meiler
-
依托单位:
Informatics Core
-
批准号:8139982
-
项目类别:
-
资助金额:$46.94万
-
财政年份:2010
-
负责人:Jens Meiler
-
依托单位:
Cheminformatics of Allosteric mGluR Modulation promotes Therapeutic Development
-
批准号:8212449
-
项目类别:
-
资助金额:$38.6万
-
财政年份:2010
-
负责人:Jens Meiler
-
依托单位:
Cheminformatics of Allosteric mGluR Modulation promotes Therapeutic Development
-
批准号:8055043
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2010
-
负责人:Jens Meiler
-
依托单位:
Informatics Core
-
批准号:8337389
-
项目类别:
-
资助金额:$31.59万
-
财政年份:2008
-
负责人:Jens Meiler
-
依托单位:
Membrane Protein Structure Elucidation from sparse NMR data (KAMP)
-
批准号:8091453
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2007
-
负责人:Jens Meiler
-
依托单位:
Membrane Protein Structure Elucidation from Limited Magnetic Resonance Data
-
批准号:9411797
-
项目类别:
-
资助金额:$2.87万
-
财政年份:2007
-
负责人:Jens Meiler
-
依托单位:
海外基金